This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO. Th...
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under...
What You Should Know: – Eir Partners (“Eir”), a middle market private equity fir...
What You Should Know: – Reveleer, the industry’s pioneering value-based care pla...
HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regene...
Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and I...
The ethical concerns of artificial intelligence have been a reocurring theme in ...
As exciting as it is to explore how far new technology can take us, it’s imperat...
The following is a guest article by Russell Graney, Founder and CEO at Aidin Hos...
By creating meaningful connections, sharing caregiving responsibilities, and dev...
EXA Capital, strategic operators and investors in growing vertical market softwa...
Strategic Acquisition will Enhance Teladoc Health’s Preventive Care and Chronic ...
Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting...
→ Celeste Warren said in a LinkedIn post that she is retiring from Merck on July...
MIAMI — Fauna Bio, a biotech that mines data on disease resistance from squirrel...
MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech indus...